Global Aromatase Inhibitors Market - Industry Trends and Forecast to 2029

Aromatase Inhibitors Market Analysis and Insights

According to a recent repory, about 255,000 cases of breast cancer are registered every year in the United States.  More than 42000 women and 500 men die of breast cancer every year in U.S. The probability of developing breast cancer increases with the age. In most cases, breast cancers are diagnosed after the age of 50. To curb the action of breast cancer tumour cells, researchers and medical professionals have introduced aromatase inhibitors in the market. The use of aromatase inhibitors has generated the desired results against these cancerous cells.  

• The aromatase inhibitors are supportive and aim to reduce the severity of the symptoms. Data Bridge Market Research analyses that the aromatase inhibitors market will grow at a CAGR of 5.60% during the forecast period of 2022 to 2029.

Aromatase Inhibitors Market Dynamics

Drivers

• Old age population base

It is scientifically proven the geriatric population base is more likely to develop breast cancer than the younger ones. Moreover, breast cancer has a high prevalence rate in postmenopausal women. As a result, there is a huge scope of growth for the aromatase inhibitors and drugs market.    

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of aromatase inhibitors market is the rising healthcare expenditure which helps in improving its infrastructure. Growth and expansion of healthcare industry especially in the developing economies would invite the use and application of nw and advanced medial technologies, equipment and drugs. This will directly increase the demand for aromatase inhibitors.

• Research and development activities

Growing number of strategic collaboration between public and private market players is inducing growth in the number of reaearch and development activities on daily basis. These research and development proficiencies are being conducted in the area of novel drugs and medical technologies which will propel the demand for aromatase inhibitors.

Furthermore, rising cases of breast cancer in both men and women, rising initiatives by public and private organizations to spread awareness and growing advancements in cancer biology and pharmacology promoting drug development are the factors that will expand the market growth rate. Other factors such as increase in the demand for effective therapies and rising adoption rate for early diagnostic procedures will positively impact the market's growth rate.

Opportunities

Rise in the level of personal disposable income and growing awareness in the developing economies pertaining to the availability of treatment options will further create lucrative market growth opportunities. Rising medical tourism globally, increasing women population base and high potential of growth in the untapped market will create enough market growth opportunities.  

Restraints/Challenges

However, high costs associated with research and development proficiencies will emerge as one of the biggest restraints for the market. Dearth of awareness and required infrastructural facilities in the underdeveloped and backward economies will further derail the market growth rate. Slow rate of approval for drugs and inhibitors and increasing cases of patent expiry will also challenge the market growth rate. 

This aromatase inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on aromatase inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to an article published in JAMA Network in August 2020, in United States from March 1, 2020, to April 18, 2020, there was a significant devcline in breast cancer diagnoses, particularly by 51.8%. However, 1 in  women suffer from breast cancer in U.S and in men it is 1 in 1000. 

Aromatase inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Aromatase Inhibitors Market

COVID-19 has given a slight setback to the market. Delay in diagnostic rate is one of the major factors responsible for this setback. Further, supply shortage of drugs and inhibitors in the market has restricted the growth during the pandemic phase. However, it must be noted that the pateints suffering from breast cancer have a higher probability of getting hit with coronavirus.

Recent Development

• Merck Co. & Inc. received the United States Food & Drug Administration approval in November 2020, for Keytruda in combination with chemotherapy in the treatment of triple-negative breast cancer.

Global Aromatase Inhibitors Market Scope

The aromatase inhibitors market is segmented on the basis of drug, mode of action, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

• Formestane
• Fadrozole
• Exemestane
• Anastrozole
• Letrozole
• Others

On the basis of drug type, the aromatase inhibitors market is segmented into formestane, fadrozole, exemestane, anastrozole, letrozole and others.

Mode of action

• Selective Inhibitors
• Non-Selective Inhibitors

The mode of action segment for aromatase inhibitors market includes selective inhibitors and non-selective inhibitors.

Route of Administration

• Oral
• Parenteral

On the basis of route of administration, the aromatase inhibitors market is segmented into oral, and parenteral.

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

On the basis of end users, the aromatase inhibitors market is segmented into hospitals, homecare, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

On the basis of distribution channel, the aromatase inhibitors market has also been segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.

Pipeline Analysis

The University of Sussex identified the role of lemur tyrosine kinase 3 (LMTK3) in the cell proliferation in breast cancer in November 2020 and since then are planning to advance the research toward developing LMTK3 specific drugs. Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd, and Merck & Co. Inc. and others are the involved in the development of potential drugs for the improvement of treatment of breast cancer.

Aromatase Inhibitors Market Regional Analysis/Insights

The aromatase inhibitors market is analysed and market size insights and trends are provided by country, drug, mode of action, route of administration, end users and distribution channel as referenced above.

The countries covered in the aromatase inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the aromatase inhibitors market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region and rising cases of breast cance rin both men and women. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing patient pool, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Aromatase Inhibitors Market Share Analysis

The aromatase inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to aromatase inhibitors market.

Some of the major players operating in the aromatase inhibitors market are Pfizer Inc, AstraZeneca, ANI Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Cipla Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Mayne Pharma Group Limited, Mylan N.V., Novartis AG., Vintage Labs, Dr. Reddy’s Laboratories Ltd, Jiangsu Hengrui Medicine Co., Ltd, Novo Nordisk A/S, Otsuka America Pharmaceutical, Inc., and WOCKHARDT among others.

SKU-52039